GlassScriptPhysician profile
Kathy D Pearson
NPI 1790781631
$10,365.86
in general payments reported to CMS, 2019-2025
73 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,404 · 2022: $2,675 · 2023: $2,789 · 2024: $863 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,831.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,455.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $1,595.66 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $585.59 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $525.44 | 2021-2025 | |
| Janssen Biotech, INC. | $488.04 | 2021-2024 | Erleada, Darzalex, Imbruvica |
| Dendreon Pharmaceuticals LLC | $472.74 | 2021-2024 | Provenge |
| Celgene Corporation | $386.10 | 2021-2024 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $382.58 | 2021-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $362.08 | 2021-2023 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $350.52 | 2021-2024 | Enhertu, Tagrisso, Lynparza |
| Pfizer INC. | $329.25 | 2021-2024 | |
| Genzyme Corporation | $309.99 | 2021-2023 | |
| Glaxosmithkline, LLC. | $291.24 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $248.94 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Coherus Oncology, INC. | $195.30 | 2021-2022 | |
| Incyte Corporation | $186.91 | 2021-2024 | Jakafi |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.